Initial Antihyperglycemic Drug Therapy Among 241 327 Adults With Newly Identified Diabetes From 2005 Through 2010: A Surveillance, Prevention, and Management of Diabetes Mellitus (SUPREME-DM) Study

Marsha A. Raebel, Stanley Xu, Glenn K. Goodrich, Emily B. Schroeder, Julie A. Schmittdiel, Jodi B. Segal, Patrick J. O'Connor, Gregory A. Nichols, Jean M. Lawrence, H. Lester Kirchner, Jennifer Elston Lafata, Melissa Butler, Katherine M. Newton, John F. Steiner

Research output: Contribution to journalArticle

Abstract

Background: Among adults with incident diabetes, data are lacking about first antihyperglycemic initiation and whether medication choice aligns with recommendations. Objective: To identify predictors of initiating any antihyperglycemic, and specifically sulfonylurea versus metformin. Methods: This retrospective cohort study included 241 327 patients from 11 US health systems, 2005 through 2010. Assessments included antihyperglycemic initiation within 6 months of diabetes identification, first medication initiated, and initiation predictors. Results: Only 40.3% (n = 97 350) started any antihyperglycemic; 75.2% (n = 73 221) started metformin. Glycosylated hemoglobin (HbA1c) predicted initiating any antihyperglycemic (HbA1c >9%, relative risk [RR] = 3.94, 95% CI = 3.82, 4.07, vs HbA1c >6.5%-7%). Age modified the HbA1c effect: at higher HbA1c, likelihood of starting antihyperglycemics differed little across ages; at lower HbA1c, older patients were less likely to start antihyperglycemics (P <.001). Individuals with elevated serum creatinine (SCr) were more likely to started on sulfonylurea (SCr = 1.4-2, RR = 2.21 [2.05, 2.39]; SCr >2, RR = 2.75 [2.30, 3.29] vs normal SCr), particularly as HbA1c increased: patients with HbA1c 8%-9% and SCr >2 were 5.59 times (2.94, 10.65) more likely to start sulfonylurea versus those with HbA1c >6.5%-7% and normal SCr. Age predicted sulfonylurea initiation (20-39 years, RR = 0.87 [0.79, 0.95]; ≥80 years, RR = 2.41 [2.20, 2.65] vs 50-59 years). Conclusions: Among adults with incident diabetes, metformin was generally the first antihyperglycemic initiated. However, 59.7% did not start any antihyperglycemic at diabetes identification. HbA1c and age predict antihyperglycemic initiation; SCr and age predict sulfonylurea initiation.

Original languageEnglish (US)
Pages (from-to)1280-1291
Number of pages12
JournalAnnals of Pharmacotherapy
Volume47
Issue number10
DOIs
StatePublished - Oct 1 2013

Keywords

  • adult
  • antihyperglycemic medication
  • incident diabetes
  • metformin
  • newly identified diabetes
  • sulfonylurea

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Initial Antihyperglycemic Drug Therapy Among 241 327 Adults With Newly Identified Diabetes From 2005 Through 2010: A Surveillance, Prevention, and Management of Diabetes Mellitus (SUPREME-DM) Study'. Together they form a unique fingerprint.

  • Cite this

    Raebel, M. A., Xu, S., Goodrich, G. K., Schroeder, E. B., Schmittdiel, J. A., Segal, J. B., O'Connor, P. J., Nichols, G. A., Lawrence, J. M., Kirchner, H. L., Elston Lafata, J., Butler, M., Newton, K. M., & Steiner, J. F. (2013). Initial Antihyperglycemic Drug Therapy Among 241 327 Adults With Newly Identified Diabetes From 2005 Through 2010: A Surveillance, Prevention, and Management of Diabetes Mellitus (SUPREME-DM) Study. Annals of Pharmacotherapy, 47(10), 1280-1291. https://doi.org/10.1177/1060028013503624